Overview Dividends

(REGN) Regeneron Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US75886F1075

Eylea, Dupixent, Libtayo, Praluent, Kevzara

REGN EPS (Earnings per Share)

EPS Growth (3Y CAGR): -2.15%
EPS Trend (3Y Correlation): 5.2%

REGN Revenue

Revenue Growth (3Y CAGR): 3.51%
Revenue Trend (3Y Correlation): 49.3%

Risk via 10d forecast
Volatility	32.8%
Value at Risk 5%th	55.0%

Reward
Sharpe Ratio	-0.39
Alpha Jensen	-26.62

Character
Hurst Exponent	0.303
Beta	0.386

Drawdowns 3y
Max DD	59.69%
Mean DD	19.36%

Description: REGN Regeneron Pharmaceuticals September 26, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a U.S.-based biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines across multiple therapeutic areas, including ophthalmology, immunology, oncology, cardiovascular, metabolic, infectious, and rare diseases.

Its flagship products generate the bulk of revenue: EYLEA (wet age-related macular degeneration and diabetic eye disease) delivered $2.0 billion in 2023 sales; Dupixent (atopic dermatitis and asthma) posted $2.5 billion; and Libtayo (cutaneous squamous-cell carcinoma) contributed $2.1 billion. Additional marketed therapies include Praluent, REGEN-COV, Kevzara, Inmazeb, ARCALYST, ZALTRAP, Evkeeza, Ordspono, and Veopoz, with a pipeline targeting eye, inflammatory, cardiovascular, metabolic, infectious, oncology, pain, and hematologic indications.

The company maintains a strong balance sheet, reporting approximately $5.5 billion of cash and marketable securities at year-end 2023, and it reinvested roughly $2.3 billion in R&D, reflecting its commitment to pipeline expansion. Key sector drivers-an aging global population increasing demand for ophthalmic and cardiovascular therapies, and sustained biotech R&D tax incentives in the United States-support Regeneron’s growth outlook.

Strategic collaborations extend Regeneron’s capabilities: a partnership with Mammoth Biosciences to develop in-vivo CRISPR-based gene-editing therapies, and an alliance with Sonoma Biotherapeutics to advance engineered regulatory T-cell treatments, both aimed at diversifying its product portfolio beyond conventional biologics.

For a deeper, data-driven valuation framework, you might explore the detailed analyst models available on ValueRay.

REGN Stock Overview

Market Cap in USD	69,106m
Sub-Industry	Biotechnology
IPO / Inception	1991-04-02
Return 12m vs S&P 500	-28.9%
Analyst Rating	4.28 of 5

REGN Dividends

Dividend Yield	0.39%
Yield on Cost 5y	0.47%
Yield CAGR 5y	0.00%
Payout Consistency	100.0%
Payout Ratio	7.8%

REGN Growth Ratios

CAGR	-2.43%
CAGR/Max DD Calmar Ratio	-0.04
CAGR/Mean DD Pain Ratio	-0.13
Current Volume	904.8k
Average Volume	842.2k

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (4.58b TTM) > 0 and > 6% of Revenue (6% = 854.9m TTM)

FCFTA 0.10 (>2.0%) and ΔFCFTA 1.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 95.14% (prev 113.2%; Δ -18.04pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.13 (>3.0%) and CFO 5.07b > Net Income 4.58b (YES >=105%, WARN >=100%)

Net Debt (199.1m) to EBITDA (5.71b) ratio: 0.03 <= 3.0 (WARN <= 3.5)

Current Ratio 4.06 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (107.2m) change vs 12m ago -7.75% (target <= -2.0% for YES)

Gross Margin 85.39% (prev 85.31%; Δ 0.08pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 36.72% (prev 36.98%; Δ -0.27pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 123.2 (EBITDA TTM 5.71b / Interest Expense TTM 42.1m) >= 6 (WARN >= 3)

Altman Z'' 9.96

(A) 0.34 = (Total Current Assets 17.98b - Total Current Liabilities 4.43b) / Total Assets 40.17b

(B) 0.87 = Retained Earnings (Balance) 35.05b / Total Assets 40.17b

warn (B) unusual magnitude: 0.87 — check mapping/units

(D) 3.81 = Book Value of Equity 35.11b / Total Liabilities 9.21b

Total Rating: 9.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 80.84

1. Piotroski 7.0pt = 2.0

2. FCF Yield 6.56% = 3.28

3. FCF Margin 29.16% = 7.29

4. Debt/Equity 0.09 = 2.50

5. Debt/Ebitda 0.03 = 2.50

6. ROIC - WACC (= 6.43)% = 8.04

7. RoE 15.31% = 1.28

8. Rev. Trend 49.33% = 3.70

9. EPS Trend 5.16% = 0.26

What is the price of REGN shares?

As of November 12, 2025, the stock is trading at USD 674.55 with a total of 904,821 shares traded.
Over the past week, the price has changed by +7.41%, over one month by +20.95%, over three months by +23.75% and over the past year by -17.95%.

Is Regeneron Pharmaceuticals a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Regeneron Pharmaceuticals (NASDAQ:REGN) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 80.84 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of REGN is around 594.74 USD . This means that REGN is currently overvalued and has a potential downside of -11.83%.

Is REGN a buy, sell or hold?

Regeneron Pharmaceuticals has received a consensus analysts rating of 4.28. Therefore, it is recommended to buy REGN.

Strong Buy: 14
Buy: 5
Hold: 5
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the REGN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	753.2	11.7%
Analysts Target Price	753.2	11.7%
ValueRay Target Price	655.3	-2.9%

REGN Fundamental Data Overview November 09, 2025

Market Cap USD = 69.11b (69.11b USD * 1.0 USD.USD)
P/E Trailing = 15.7719
P/E Forward = 15.456
P/S = 4.8503
P/B = 2.1241
P/EG = 1.154
Beta = 0.386
Revenue TTM = 14.25b USD
EBIT TTM = 5.19b USD
EBITDA TTM = 5.71b USD
Long Term Debt = 1.98b USD (from longTermDebt, last fiscal year)
Short Term Debt = unknown (none)
Debt = 2.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 199.1m USD (from netDebt column, last quarter)
Enterprise Value = 63.37b USD (69.11b + Debt 2.71b - CCE 8.44b)
Interest Coverage Ratio = 123.2 (Ebit TTM 5.19b / Interest Expense TTM 42.1m)
FCF Yield = 6.56% (FCF TTM 4.15b / Enterprise Value 63.37b)
FCF Margin = 29.16% (FCF TTM 4.15b / Revenue TTM 14.25b)
Net Margin = 32.13% (Net Income TTM 4.58b / Revenue TTM 14.25b)
Gross Margin = 85.39% ((Revenue TTM 14.25b - Cost of Revenue TTM 2.08b) / Revenue TTM)
Gross Margin QoQ = 86.11% (prev 85.58%)
Tobins Q-Ratio = 1.58 (Enterprise Value 63.37b / Total Assets 40.17b)
Interest Expense / Debt = 0.71% (Interest Expense 19.3m / Debt 2.71b)
Taxrate = 17.20% (303.3m / 1.76b)
NOPAT = 4.29b (EBIT 5.19b * (1 - 17.20%))
Current Ratio = 4.06 (Total Current Assets 17.98b / Total Current Liabilities 4.43b)
Debt / Equity = 0.09 (Debt 2.71b / totalStockholderEquity, last quarter 30.96b)
Debt / EBITDA = 0.03 (Net Debt 199.1m / EBITDA 5.71b)
Debt / FCF = 0.05 (Net Debt 199.1m / FCF TTM 4.15b)
Total Stockholder Equity = 29.91b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.40% (Net Income 4.58b / Total Assets 40.17b)
RoE = 15.31% (Net Income TTM 4.58b / Total Stockholder Equity 29.91b)
RoCE = 16.26% (EBIT 5.19b / Capital Employed (Equity 29.91b + L.T.Debt 1.98b))
RoIC = 13.62% (NOPAT 4.29b / Invested Capital 31.54b)
WACC = 7.18% (E(69.11b)/V(71.81b) * Re(7.44%) + D(2.71b)/V(71.81b) * Rd(0.71%) * (1-Tc(0.17)))
Discount Rate = 7.44% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -81.65 | Cagr: -2.94%
[DCF Debug] Terminal Value 75.66% ; FCFE base≈3.84b ; Y1≈3.26b ; Y5≈2.50b
Fair Price DCF = 442.7 (DCF Value 45.73b / Shares Outstanding 103.3m; 5y FCF grow -18.28% → 3.0% )
EPS Correlation: 5.16 | EPS CAGR: -2.15% | SUE: 1.43 | # QB: 2
Revenue Correlation: 49.33 | Revenue CAGR: 3.51% | SUE: 0.91 | # QB: 2

Additional Sources for REGN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle